Combining MRI radiomics, hypoxia gene signature score and clinical variables for prediction of biochemical recurrence-free survival after radiotherapy in prostate cancer
Jim Zhong(University of Leeds), Andrew Scarsbrook(University of Leeds), Alan McWilliam(National Health Service), Peter Hoskin(University of Manchester), Oliver Hulson(National Health Service), A. Davey(Cancer Research UK Manchester Institute), Martin Swinton(The Christie NHS Foundation Trust), Ananya Choudhury(University of Manchester), Russell Frood(University of Leeds), Sarah Brown(University of Leeds), Catharine West(University of Manchester), David L. Buckley(University of Florida), Ann Henry(University of Leeds), Jane Shortall(National Health Service), Kimberley Reaves(University of Manchester), Mark Reardon(University of Manchester)
Cited by 5
Related Papers
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci
|Nature Genetics|2018|1k
The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies
|Clinical and Translational Radiation Oncology|2018|932